BHST bioharvest.com: Enterprise Value-to-Revenue Multiple

BioHarvest Sciences, Inc. (BHST) - corporate logo

Partnerships with dietary supplement manufacturers to create plant metabolites impact financial stability, as evidenced by the EV/Sales ratio of BioHarvest Sciences (BHST). The value 1020.71 captures the current state of this parameter. Optimization is possible through the Inertia platform, which guarantees long-term margins on raw materials, and growing confidence in the science-based innovations of BioHarvest Sciences in the field of cellular medicine.

BioHarvest - BHST EV/Sales Multiple (period 11/23/2025 - 11/20/2026)

Financial and market metric breakdowns for BioHarvest (BHST)

- market price and analyst price targets:
- company stock capitalization data:
Fundamental company valuation:BHST, bioharvest.com
Product sample of BioHarvest Sciences, Inc.

This multiple determines the enterprise value of the business relative to sales volume. It measures the premium the market is willing to pay per unit of revenue, excluding the impact of the financing structure. By analyzing the valuation level via EV/Sales, an investor can identify whether an asset is overvalued or undervalued. For BioHarvest Sciences (BHST), this indicator reflects market expectations regarding the scaling of the VINIA platform. Sales growth driven by B2B contracts and expansion in the US should lead to an optimization of this ratio.

Competitor analysis

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple eXoZymes Inc (EXOZ)|ORMP (oramed.com) - EV/Sales Multiple|Company Value to Revenue Ratio ENTX (Entera Bio)|Enterprise Value-to-Revenue Ratio MindWalk (HYFT)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio